Development of a world-leading preclinical drug development company specialising in ophthalmology through innovative state-of-the-art preclinical models and expert provision of data interpretation.

通过创新的、最先进的临床前模型和专家提供的数据解释，发展一家世界领先的临床前药物开发公司，专门从事眼科领域。

• 批准号: 10035984
• 金额: $ 37.11万
• 依托单位: MEDINECT BIOSERVICES LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10035984
• 关键词: Development; world; leading; preclinical; drug

Diabetic Retinopathy (DR) and Age-related macular degeneration (AMD), termed retinal disease herein, are the leading cause of vision loss worldwide, affecting over 300 million people. Current treatment strategies for retinal disease are limited, with poor efficacy observed in late-stage clinical trials of promising drugs. This is attributed to poor preclinical models of disease.Over 50% of the total research and development (R&D) by biotechnology and pharmaceutical companies is outsourced. Extensive market research conducted during ICURe, revealed key factors contributing to substandard preclinical drug development. These included: outdated and inappropriate preclinical models; suboptimal study design; a lack of collaborative data interpretation; a lack of technical quality and a poor customer service provision.MediNect builds on 30 years' intensive R&D of preclinical models in retinal disease to deliver state-of-the-art models that target disease features currently not available to the market. MediNect has a wealth of technical and interpretive know-how, which provides optimal study design, practical technique and data interpretation. MediNect will function as a company to offer a collaborative approach to preclinical drug development, with access to test novel drugs in ten well-established models of retinal disease and two novel models. Validated to industry standard, the diabetic macular ischaemia (DMI) and sub-retinal fibrosis (SRF) model will be used to give greater insight into novel drugs targeting late-stage retinal disease, respectively. Our novel models are superior to current methods that use models that replicate early-stage disease features.In addition, MediNect has a catalogue of five state-of-the-art genetically modified models and five in development that target unmet areas of retinal disease features that are superior to current methods and will cement MediNect's position as market leaders in ophthalmology drug development research.MediNect's team of world leading experts and researchers will be complimented by a gold-standard client-focused offering to deliver oncology-CRO standard communication streams, study planning providing greater insight into drug development.MediNect will help the urgent need for development of better vision-restoring drugs, helping 60 million people worldwide suffering from late-stage retinal disease.

糖尿病性视网膜病（DR）和与年龄相关的黄斑变性（AMD）称为视网膜疾病，是全球视力丧失的主要原因，影响了3亿多人。当前的视网膜疾病治疗策略受到限制，在有希望的药物的后期临床试验中观察到疗效差。这归因于疾病的不良临床前模型。生物技术和制药公司的总研发（R＆D）的50％被外包。在ICURE期间进行的广泛市场研究揭示了导致临床前药物开发的关键因素。其中包括：过时和不适当的临床前模型；次优研究设计；缺乏协作数据解释；缺乏技术质量和不良的客户服务提供。MedInect建立在视网膜疾病中的临床前模型的30年密集的研发上，以提供最先进的模型，这些模型针对目前尚不可用于市场的疾病特征。 Medinect拥有丰富的技术和解释性知识，其中提供了最佳的研究设计，实用技术和数据解释。 Medinect将充当一家公司，以提供临床前药物开发的协作方法，并可以在十种公认的视网膜疾病模型和两个新型模型中使用测试新药物。经行业标准验证，糖尿病性黄斑缺血（DMI）和视网膜下纤维化（SRF）模型将分别用于对靶向晚期视网膜疾病的新型药物进行更深入的了解。我们的新型模型优于使用复制早期疾病特征的模型的当前方法。此外，Medinect拥有五个最先进的转基因模型的目录，而在开发中具有五个目标，这些模型针对的是未完成的疾病特征的未满足领域，这些领域优于当前方法，并且将巩固MedInect MedInect在Ophthallogic necter.Medinect of Goldthallogic never.Medinect的领导者中的地位。以客户为中心的服务提供肿瘤科学标准通信流，提供对药物开发的洞察力的研究计划。MedInect将有助于迫切需要开发更好的视力恢复药物，从而帮助全球6000万人患有晚期视网膜疾病。